Patients’ perspectives regarding long-term warfarin therapy and the potential transition to new oral anticoagulant therapy

Therapeutic Advances in Drug Safety

Volumn 5, Issue 6, 2014, Pages 220-228

  Gebler Hughes, Elizabeth S ^a   Kemp, Linda ^a   Bond, Malcolm J ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

INR; oral anticoagulants; patient preferences; vitamin K antagonists; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; AUSTRALIA; CONFUSION (UNCERTAINTY); DRUG SAFETY; FEMALE; FOOD; FOOD DRUG INTERACTION; GENERAL PRACTICE; GROUPS BY AGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; TREATMENT DURATION; URBAN RURAL DIFFERENCE;

EID: 84911038179     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098614552073     Document Type: Article

References (21)

1. Ageno W. Gallus A. Wittkowsky A. Crowther M. Hylek E. Palareti G. (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2): e44S–e88S.
2. Becattini C. Vedovati M. Agnelli G. (2012) Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res 129: 392–400.
3. Camm A. (2009) The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin. Eur Heart J 30: 2554–2555.
4. Connolly S. Ezekowitz M. Yusuf S. Eikelboom J. Oldgren J. Parekh A. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139–1151.
5. Corbi I. Dantas R. Pelegrino F. Carvalh A. (2011) Health related quality of life of patients undergoing oral anticoagulation therapy. Rev Lat Am Enfermagem 19: 865–873.
6. Courtenay W. (2000) Constructions of masculinity and their influence on men–s well-being: a theory of gender and health. Soc Sci Med 50: 1385–1401.
7. Das A. Ahmed A. Corrado O. West R. (2009) Quality of life of elderly people on warfarin for atrial fibrillation. Age Aging 38: 751–754.
8. Garcia D. Libby E. Crowther M. (2010) The new oral anticoagulants. Blood 115: 15–20.
9. Granger C. Alexander J. McMurray J. Lopes R. Hylek E. Hanna M. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981–992.
10. Johnson M. (2013) Transitions of care in patients receiving oral anticoagulants: general principles, procedures, and impact of new oral anticoagulants. J Cardiovas Nurs 28: 54–65.
11. Kneeland P. Fang M. (2010) Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 4: 51–60.
12. Lancaster T. Singer D. Sheehan M. Oertel L. Maraventano S. Hughes R. (1991) The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Arch Intern Med 151: 1944–1949.
13. Lopes R. Alexander J. Al-Khatib S. Ansell J. Diaz R. Easton J. (2010) Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159: 331–339.
14. Monz B. Connolly S. Korhonen M. Noack H. Pooley J. (2013) Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol 168: 2540–2547.
15. Patel M. Mahaffey K. Garg J. Pan G. Singer D. Hacke E. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883–891.
16. Perez A. Eraso L. Merli G. (2013) Implications of new anticoagulants in primary practice. Int J Clin Pract 67: 139–156.
17. Pugh D. Pugh J. Mead G. (2011) Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 40: 675–683.
18. Smith M. Christensen N. Wang S. Strohecker J. Day J. Weiss J. (2010) Warfarin knowledge in patients with atrial fibrillation: Implications for safety, efficacy, and education strategies. Cardiology 116: 61–69.
19. Tadros R. Shakib S. (2010) Warfarin – indications, risks and drug interactions. Aust Fam Physician 39: 476–479.
20. Weisman C. Teitelbaum M. (1989) Women and health care communication. Patient Educ Couns 13: 183–199.
21. Weitz J. Gross P. (2012) New oral anticoagulants: which one should my patient use? Hematology Am Soc Hematol Educ Program 2012: 536–540.